Prognostic significance and molecular associations of CDKN2A (p16) promoter methylation and loss of expression in colorectal cancer

被引：0
|
作者：
Shima, Kaori
Nosho, Katsuhiko
Baba, Yoshifumi
Cantor, Mami
Giovannucci, Edward L.
Fuchs, Charles S.
Ogino, Shuji
机构：
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/1538-7445.AM10-4639
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4639
引用
收藏
页数：3
相关论文
共 50 条
  • [41] CDKN2A and MTAP Deletions in Peritoneal Mesotheliomas: Correlation with Loss of p16 Protein Expression and Survival
    Krasinskas, A. M.
    Bartlett, D.
    Cieply, K.
    Dacic, S.
    LABORATORY INVESTIGATION, 2009, 89 : 136A - 136A
  • [42] Loss of p16 expression and copy number changes of CDKN2A in a spectrum of spitzoid melanocytic lesions
    Harms, Paul W.
    Hocker, Thomas L.
    Zhao, Lili
    Chan, May P.
    Andea, Aleodor A.
    Wang, Min
    Harms, Kelly L.
    Wang, Michael L.
    Carskadon, Shannon
    Palanisamy, Nallasivam
    Fullen, Douglas R.
    HUMAN PATHOLOGY, 2016, 58 : 152 - 160
  • [43] Comparing loss of p16 and MTAP expression in detecting CDKN2A homozygous deletion in pleomorphic xanthoastrocytoma
    Vizcaino, M. Adelita
    Giannini, Caterina
    Vaubel, Rachael A.
    Nguyen, Aivi T.
    Trejo-Lopez, Jorge A.
    Raghunathan, Aditya
    Jenkins, Sarah M.
    Jenkins, Robert B.
    Mendoza, Cinthya J. Zepeda
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2024, 83 (12): : 1003 - 1009
  • [44] Loss of p16 (CDKN2A) Expression Is Rare in Dedifferentiated Liposarcoma and Does Not Promote Tumor Progression
    Kang, Y.
    Horvai, A. E.
    LABORATORY INVESTIGATION, 2014, 94 : 19A - 19A
  • [45] CDKN2A/p16 inactivation in the prognosis of oligodendrogliomas
    Bortolotto, S
    Chiadò-Piat, L
    Cavalla, P
    Bosone, I
    Chiò, A
    Mauro, A
    Schiffer, D
    INTERNATIONAL JOURNAL OF CANCER, 2000, 88 (04) : 554 - 557
  • [46] Study of p16 promoter methylation in Egyptian colorectal cancer patients
    Karam, Rehab A.
    Zidan, Haidy E.
    Abd Elrahman, Tamer M.
    Badr, Samir A.
    Amer, Samar A.
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2019, 120 (05) : 8581 - 8587
  • [47] Clinicopathological Significance and Potential Drug Target of CDKN2A/p16 in Endometrial Carcinoma
    Li Su
    Hanwei Wang
    Jingwei Miao
    Ying Liang
    Scientific Reports, 5
  • [48] Clinicopathological Significance and Potential Drug Target of CDKN2A/p16 in Endometrial Carcinoma
    Su, Li
    Wang, Hanwei
    Miao, Jingwei
    Liang, Ying
    SCIENTIFIC REPORTS, 2015, 5
  • [49] Tumor suppressor gene p16 (CDKN2A) mutation status and promoter inactivation in head and neck cancer
    Riese, U
    Dahse, R
    Fiedler, W
    Theuer, C
    Koscielny, S
    Ernst, G
    Beleites, E
    Claussen, U
    von Eggeling, F
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 1999, 4 (01) : 61 - 65
  • [50] Loss of p16 expression is a sensitive marker of CDKN2A homozygous deletion in higher-grade meningiomas
    Tang, Vivian
    Lucas, Calixto-Hope
    Lu, Rufei
    Mirchia, Kanish
    Sullivan, Daniel
    Van Ziffle, Jessica
    Devine, Patrick
    Lee, Julieann
    Phillips, Joanna
    Perry, Arie
    Raleigh, David
    Solomon, David
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2022, 81 (06): : 469 - 470
12345